Genmab A/S
CSE:GMAB
Genmab A/S
CSE:GMAB
Price:
1 957.5 DKK
0.05%
Market Closed
Updated:
May 2, 2024
Genmab A/S
Net Income (Common)
|
Genmab A/S
Net Income (Common) Peer Comparison
Comparables:
ZEAL
ASND
B
BAVA
BIOPOR
SANION
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Net Income (Common)
kr4.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
24%
|
CAGR 10-Years
44%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Net Income (Common)
-kr703.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Income (Common)
-€481.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Income (Common)
kr1.5B
|
CAGR 3-Years
75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Net Income (Common)
-kr56.3m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Saniona AB
STO:SANION
|
Net Income (Common)
-kr95.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
See Also
What is Genmab A/S's Net Income (Common)?
Net Income (Common)
4.4B
DKK
4.4B
DKK
Based on the financial report for Dec 31, 2023, Genmab A/S's Net Income (Common) amounts to 4.4B DKK.
What is Genmab A/S's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
44%
44%
Over the last year, the Net Income (Common) growth was -20%. The average annual Net Income (Common) growth rates for Genmab A/S have been -3% over the past three years , 24% over the past five years , and 44% over the past ten years .
You don't have any saved screeners yet
